诺和诺德以33亿美元完成对Dicerna PharmPharmticals的收购

09:26 AM EST, 12/28/2021 (MT Newswires) -- Novo Nordisk B (NOVO-B.CO) said Tuesday that it completed the acquisition of Dicerna Pharmaceuticals for $38.25 per share in cash, reflecting an equity value of $3.3 billion.

Upon expiration of the company's tender offer for Dicerna, about 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer, representing about 82.6% of the outstanding shares of Dicerna's common stock.

Dicerna has now become a wholly owned subsidiary of Novo Nordisk, and its common stock will be delisted from the Nasdaq Global Select Market.

Shares of Novo Nordisk were up nearly 1% in recent trading.